UK Markets open in 6 hrs 26 mins

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
15.00+0.10 (+0.67%)
At close: 4:00PM EDT
15.00 0.00 (0.00%)
After hours: 04:09PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close14.90
Open14.98
Bid14.57 x 800
Ask14.59 x 1000
Day's range14.50 - 15.14
52-week range9.25 - 25.46
Volume786,261
Avg. volume590,025
Market cap934.876M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
    Business Wire

    Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

    SEATTLE, Jun 14, 2021--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult P

  • Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
    Business Wire

    Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

    Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article "Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modu

  • Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
    Business Wire

    Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

    Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT.